Influence of the storage orientation on the aerodynamic particle size of a suspension metered dose inhaler containing propellant HFA-227

Drug Development and Industrial Pharmacy

Volumn 29, Issue 6, 2003, Pages 631-639

  Berry, Julianne ^a   Kline, Lukeysha C ^a   Hart, John L ^a   Sequeira, Joel ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cascade impaction; Laser diffraction; Leachables; Metered dose inhalers; Particle size; Storage orientation

Indexed keywords

APAFLURANE; PROPELLANT;

ARTICLE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STORAGE; LASER DIFFRACTION; METERED DOSE INHALER; PARTICLE SIZE;

ADSORPTION; AEROSOL PROPELLANTS; CHEMISTRY, PHARMACEUTICAL; DRUG STORAGE; EXCIPIENTS; HYDROCARBONS, FLUORINATED; METERED DOSE INHALERS; PARTICLE SIZE; SUSPENSIONS;

EID: 0037817480     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120021312     Document Type: Article

References (33)

1. Dolovich, M. Characterization of medical aerosols: physical and clinical requirements for new inhalers. Aerosol Science and Technology 1995, 22, 392-399.
2. Elvecrog, J. Metered dose inhalers in a CFC-free future. Pharmaceutical Technology Europe 1997, 9 (1), 52-55.
3. Keller, M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. International Journal of Pharmaceutics 1999, 186, 81-90.
4. Dunbar, C.A.; Watkins, A.P.; Miller, J.F. Characterization of the pMDI spray using numerical methods. Proceedings of ICLASS 1997, August 18-22, 876-883.
5. Dunbar, C.A. Atomization mechanisms of the pressurized metered dose inhaler. Particulate Science and Technology 1998, 15 (3-4), 253-271.
6. Polli, G.P.; Grim, W.M.; Bacher, F.A.; Yunker, M.H. Influence of formulation on aerosol particle size. Journal of Pharmaceutical Sciences 1969, 58 (4), 484-486.
7. Moren, F. Drug Deposition of pressurized inhalation aerosols I. influence of actuator tube design. International Journal of Pharmaceutics 1978, 1, 205-212.
8. Kim, C.S.; Trujillo, D.; Sackner, M.A. Size aspects of metered dose inhalers. American Review of Respiratory Disease 1985, 132 (1), 137-142.
9. Clark, A.R. The physics of aerosol formation by MDIs - limitations of the current approach. Journal of Biopharmaceutical Sciences 1992, 3 (1/2), 69-76.
10. Brambilla, G.; Ganderton, D.; Garzia, R.; Lewis, D.; Meakin, B.; Ventura, P. Modulation of aerosol clouds produced by pressurized inhalation aerosols. International Journal of Pharmaceutics 1999, 186 (1), 53-61.
11. Dolovich, M.B.; Ruffin, R.E.; Roberts, R.; Newhouse, M.T. Optimal delivery of aerosols from metered dose inhalers. Chest 80 (suppl.) 1981, 911-915.
12. Meyer, K.C.; Auerbach, W.R. Drug delivery to the lung. In Polymeric Site-Specific Pharmacotherapy; Domb, A.J., Ed.; John Wiley and Sons: New York, 1994; 347-367
13. Pritchard, J.N. The influence of lung deposition on clinical response. Journal of Medicine 2001, 14 (1), S19-S26.
14. Leach, C.L.; Davidson, P.J.; Boudreau, R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. European Respiratory Journal 1998, 12, 1346-1353.
15. Matthys, H. Chlorofluorocarbon-free aerosol therapy in patients with pulmonary airflow obstruction. Respiration 1996, 63 (3), 321-324.
16. Byron, P.R.; Miller, N.C.; Blondino, F.E.; Visich, J.E.; Ward G.H. Some aspects of alternative propellant solvency. Respiratory Drug Delivery IV 1994, 239-242.
17. Vervaet, C.; Byron, P.R. Drug-surfactant-propellant interactions in HFA-formulations. International Journal of Pharmaceutics 1999, 186, 13-30.
18. Cummings R.H. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. Journal of Allergy and Clinical Immunology 1999, S230-S235.
19. McDonald, K.J.; Martin, G.P. Transition to CFC-free metered dose inhalers - into the new millennium. International Journal of Pharmaceutics 2000, 201, 89-107.
20. Milosovich, S. Particle size determination via cascade impaction. Pharmaceutical Technology 1992, 16, 82-86.
21. Johnsen, M.A. Properties of aerosol particles. Spray Technology and Marketing 1992, 2 (8), 46-55.
22. United States Pharmacopeia 25, General Chapter 601 (2001), 1969-1980.
23. Sequeira, J.; Berry, J.; Sharpe, S.; Naini, V.; Hart, J. A comparison of metered dose inhaler particle size distribution by andersen cascade impaction using two types of entry ports. Respiratory Drug Delivery VIII 2002, 2, 573-576.
24. Ranucci, J. Dynamic plume-particle size analysis using laser diffraction. Pharmaceutical Technology 1992, 16, 108-114.
25. Witt, W.; Rothele, S. Laser diffraction - unlimited? Part. Syst. Charact 1996, 13, 280-286.
26. Le Brun, P.P.H.; de Boer, A.H.; Gjaltema, D.; Hagedoorn, P.; Heijerman, H.G.M.; Frijlink, H.W., Inhalation of tobramycin in cystic fibrosis. International Journal of Pharmaceutics 1999, 189 (2), 205-214.
27. Sethi, S.K.; Norwood, D.L.; Haywood P.A.; Prime D. Impact of extractable testing on MDI development programs. Journal of Biopharmaceutical Sciences 1992, 3 (1/2), 063-068.
28. Howlett, D. Pharmaceutical aerosol valves - an overview. Spray Technology and Marketing 1994, 18-22.
29. Hickey, A.J.; Dalby, R.N.; Byron P.R. Effects of surfactants on aerosol powders in suspension. Implications for airborne particle size. International Journal of Pharmaceutics 1988, 42 (1-3), 267-270.
30. Ranucci, J.A.; Cooper, D.; Sethachutkul, K. Effect of actuator design on metered dose inhaler plume particle size. Pharmaceutical Technology 1992, 16, 84-92.
31. Dalby, R.N.; Byron, P.R. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharmaceutical Research 1988, 5 (1), 36-39.
32. Evans, R.M.; Farr, S.J.; Armstrong, N.A.; Chatham, S.M. Formulation and in vitro evaluation of pressurized inhalation aerosols containing isotropic systems of lecithin and water. Pharmaceutical Research 1991, 8 (5), 629-635.
33. Tzou, T.Z. Aerodynamic particle size of metered dose inhalers determined by the quartz crystal microbalance and the andersen cascade impactor. International Journal of Pharmaceutics 1999, 186, 71-79.